Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP71: Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Li*1, J. R. Friedman1, C. Marano1, H. Zhang1, F. Yang1, B. G. Feagan2, L. Peyrin-Biroulet3, G. De Hertogh4

1Janssen Research and Development, LLC, Spring House, USA, 2Robarts Research Institute, Robarts Clinical Trials, London, Canada, 3Nancy University Hospital, Université de Lorraine, Nancy, France, 4University Hospitals KU, Leuven, Belgium

DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia

ECCO '19 Copenhagen

Year: 2019
Authors:

M. de Jong*1, H. Kanne1, L. Nissen2, I. Nagtegaal3, J. Drenth1, L. Derikx1,2, F. Hoentjen1

1Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands, 2Jeroen Bosch Hospital, Gastroenterology and Hepatology, s'Hertogenbosch, The Netherlands, 3Radboud University Medical Center, Pathology, Nijmegen, The Netherlands

DOP73: Treatment of perianal fistulas in Crohn’s disease, seton vs. anti-TNF vs. surgical closure following anti-TNF (PISA): a randomised controlled trial

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Wasmann*1, E. J. de Groof2, M. Stellingwerf1, G. D'Haens3, C. Ponsioen3, K. Gecse3, M. Dijkgraaf4, W. Bemelman2, C. Buskens2

1Amsterdam UMC, Department of Surgery and Gastroenterology, Amsterdam, The Netherlands, 2Amsterdam UMC, Department of Surgery, Amsterdam, The Netherlands, 3Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 4Amsterdam UMC, Clinical Research Unit and Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam, The Netherlands

DOP74: Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Biron*1, P. Seksik2, M. Nachury3, Y. Bouhnik4, A. Amiot5, S. Viennot6, M. Serrero7, M. Fumery8, M. Allez9, L. Siproudhis10, A. Buisson11, G. Pineton de Chambrun12, V. Abitbol13, S. Nancey14, L. Caillo15, L. Plastaras16, L. Armengol-Debeir17, E. Chanteloup18, M. Simon19, N. Dib20, S. Rajca21, M. Amil22, L. Peyrin-Biroulet23, L. Vuitton24

1CHU Jean Minjoz, Gastroenterology, Besançon, France, 2Hôpital Saint-Antoine, Gastroentérologie, Paris, France, 3CHRU Lille, Gastroentérologie, Lille, France, 4Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, 5Hôpital Henri-Mondor, Gastroentérologie, Paris, France, 6CHRU Caen, Gastroentérologie, Caen, France, 7APHM Hôpital Nord, Gastroentérologie, Marseille, France, 8CHRU Amiens, Gastroentérologie, Amiens, France, 9Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, 10CHRU Rennes, Gastroentérologie, Rennes, France, 11CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, 12CHRU Montpellier, Gastroentérologie, Montpellier, France, 13Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, 14Groupement Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, 15CHU Nîmes, Gastroentérologie, Nîmes, France, 16Hôpital Pasteur, Gastroentérologie, Colmar, France, 17CHRU Rouen, Gastroentérologie, Rouen, France, 18Hôpital Saint-Joseph, Gastroentérologie, Paris, France, 19Institut Mutualiste Monsouris, Gastroentérologie, Paris, France, 20CHRU Angers, Gastroentérologie, Angers, France, 21Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, 22CHD Vendée, Gastroentérologie, La Roche-sur-Yon, France, 23CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, 24CHRU Jean Minjoz, Gastroentérologie, Besançon, France

DOP75: Surgery and hospitalisations rates in inflammatory bowel disease patients in the Québec provincial database from 199–6 to 2015

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Verdon*1, J. Reinglas1, J. Coulombe2, L. Gonczi3, T. Bessissow1, W. Afif1, M. Vutcovici4, G. Wild1, E. Seidman1, A. Bitton1, P. Brassard5,6, P. Lakatos1

1McGill University Health Center, Division of Gastroenterology, Montreal, Canada, 2Lady Davis Research Institute, Jewish General Hospital, Centre for Clinical Epidemiology, Montreal, Canada, 3Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, 4McGill University Health Centre, Division of Gastroenterology, Montreal, Canada, 5Biostatistics and Occupational Health, Department of Epidemiology, Montreal, Canada, 6McGill University, Department of Medicine, Montreal, Canada

DOP76: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease in a nationwide cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Nordholm-Carstensen*1, N. Qvist2, B. Højgaard3, C. Halling3, M. Carstensen4, N-P. Ipland4, J. Burisch5

1Zealand University Hospital, Department of Surgery, Roskilde, Denmark, 2Odense University Hospital, Department of Surgery, Odense, Denmark, 3VIVE – The Danish Center for Social Science Research, Copenhagen, Denmark, 4Takeda Pharma A/S, Taastrup, Denmark, 5Danish Centre for eHealth and Epidemiology, Frederikssund, Denmark

DOP77: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's disease

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Knyazev1, A. Kagramanova*1, A. Lishchinskaya1, M. Zvyaglova1, D. Kulakov1, A. Parfenov1

1Moscow Clinical Scientific Center named after A. S. Loginov, Department of Inflammatory Bowel Diseases, Moscow, Russian Federation

DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Biron*1, P. Seksik2, M. Nachury3, S. Nancey4, Y. Bouhnik5, M. Serrero6, L. Armengol-Debeir7, A. Buisson8, M-L. Tran Minh9, C. Zallot10, M. Fumery11, G. Bouguen12, V. Abitbol13, S. Viennot14, E. Chanteloup15, S. Rajca16, N. Dib17, L. Peyrin-Biroulet10, L. Vuitton18

1CHU Jean Minjoz, Gastroenterology, Besançon, France, 2Hôpital Saint-Antoine, Gastroentérologie, Paris, France, 3CHRU Lille, Gastroentérologie, Lille, France, 4Groupement Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, 5Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, 6APHM Hôpital Nord, Gastroentérologie, Marseille, France, 7CHRU Rouen, Gastroentérologie, Rouen, France, 8CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, 9Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, 10CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, 11CHRU Amiens, Gastroentérologie, Amiens, France, 12CHRU Rennes, Gastroentérologie, Rennes, France, 13Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, 14CHRU Caen, Gastroentérologie, Caen, France, 15Hôpital Saint-Joseph, Gastroentérologie, Paris, France, 16Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, 17CHRU Angers, Gastroentérologie, Angers, France, 18CHRU Jean Minjoz, Gastroentérologie, Besançon, France

DOP79: Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials

ECCO '19 Copenhagen

Year: 2019
Authors:

B. G. Feagan*1, B. E. Sands2, R. Lirio3, T. Lissoos3, J. Wang3, D. Feng3, K. Lasch3

1Robarts Clinical Trials, Western University, London, Ontario, Canada, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, NY, USA, 3Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA

DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Buisson*1, D. Laharie2, S. Nancey3, X. Hébuterne4, X. Roblin5, M. Nachury6, L. Peyrin-Biroulet7, M. Fumery8, F. Goutorbe1, D. Coban1, C. Allimant1, M. Reymond1, E. Vazeille1, B. Pereira1, M. Goutte1, G. Bommelaer1

1University Hospital Estaing, IBD unit, Clermont-Ferrand, France, 2CHU Bordeaux, Bordeaux, France, 3HCL Lyon-Sud, Lyon, France, 4CHU Nice, Nice, France, 5CHU Saint-Etienne, Saint-Etienne, France, 6CHU Lille, Lille, France, 7CHU Nancy, Nancy, France, 8CHU Amiens, Amiens, France

DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. L. Hamilton*1, P. P. De Cruz1,2, E. K. Wright3, L. Okada4, M. Hale4, L. Mimms4, A. Jain4, M. A. Kamm1

1The University of Melbourne and St Vincent's Hospital, Melbourne, Department of Medicine and Department of Gastroenterology, Melbourne, Australia, 2Austin Health, Department of Gastroenterology, Melbourne, Australia, 3St Vincent's Hospital, Department of Gastroenterolgy, Melbourne, Australia, 4Prometheus Laboratories Inc., San Diego, USA

DOP82: Direct and indirect costs of inflammatory bowel disease in the biological era; 10 years of follow-up in a Danish population-based inception cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Lo*1, I. Vind1, M. K. Vester-Andersen1,2, F. Bendtsen1, J. Burisch1

1Copenhagen University Hospital Hvidovre, The Gastro Unit, Hvidovre, Denmark, 2Zealand University Hospital, Medical Department, Koege, Denmark

DOP83: Association of FUT2 and ABO with Crohn’s disease in Koreans

ECCO '19 Copenhagen

Year: 2019
Authors:

H-S. Lee*1,2, B. M. Kim2, S. Jung2, M. Hong2, K. Kim2, J. W. Moon2, J. Baek2, S. W. Hwang3, S. H. Park3, S-K. Yang3, K. Song2, B. D. Ye3

1KU Leuven, Department of Human Genetics, Laboratory of Complex Genetics, Leuven, Belgium, 2University of Ulsan College of Medicine, Department of Biochemistry and Molecular Biology, Seoul, South Korea, 3Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Inflammatory Bowel Disease Center, Seoul, South Korea

DOP84: Nationwide incidence and prevalence of paediatric inflammatory bowel disease in Scotland 2015–2017 demonstrates the highest paediatric prevalence rate recorded worldwide

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Burgess*1,2, P. Henderson1,2, I. Chalmers3, R. Harris4, R. Hansen4, R. Russell4, D. Wilson1,2

1University of Edinburgh, Child Life and Health, Edinburgh, UK, 2Royal Hospital for Sick Children, Paediatric Gastroenterology and Nutrition, Edinburgh, UK, 3Royal Aberdeen Children's Hospital, Paediatric Gastroenterology and Nutrition, Aberdeen, UK, 4Royal Hospital for Children, Paediatric Gastroenterology and Nutrition, Glasgow, UK

DOP85: Rising depression and antidepressant use amongst inflammatory bowel disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Blackwell*1, S. Saxena2, C. Alexakis1, E. Cecil2, A. Bottle2, I. Petersen3,4, M. Hotopf5, R. Pollok1

1St George's Healthcare NHS Trust, Gastroenterology, London, UK, 2Imperial College London, School of Public Health, London, UK, 3University College London, Epidemiology and Health Informatics, London, UK, 4Aarhus University, Biostatistics, Aarhus, Denmark, 5King's College London, Institute of Psychiatry, London, UK

DOP86: Risk for development of inflammatory bowel disease under inhibition of interleukin 17 in psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis: a review and meta-analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Eigner*1, J. Burisch2, W. Reinisch1

1Medical University of Vienna, Medicine III, Division Gastroenterology and Hepatology, Vienna, Austria, 2Danish Centre for eHealth and Epidemiology, Department of Gastroenterology, Frederikssund, Denmark

DOP87: Multi-parameter datasets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)

ECCO '19 Copenhagen

Year: 2019
Authors:

G-R. Jones*1,2, M. Lyons2, N. Plevris1, P. Jenkinson1, C. Bisset1, J. Fulforth1, C. S. Chuah1, S. Minnis1, S-L. Gillespie1, W. Brindle1, C. Burgess3, P. Henderson3, D. Wilson3, C. Lees1

1Western General Hospital, Gastroenterology, Edinburgh, UK, 2University of Edinburgh, Gastroenterology, Edinburgh, UK, 3Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, UK

DOP88: Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in inflammatory bowel disease patients: a nationwide Danish cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

S. B. Thomsen*1, K. H. Allin2, J. Burisch2, C. B. Jensen2, S. Hansen2, L. L. Gluud1, K. Theede1, M. Kiszka-Kanowitz1, A. M. Nielsen1, T. Jess2

1Copenhagen University Hospital Hvidovre, Gastrounit, Medical Division, Copenhagen, Denmark, 2Bispebjerg and Frederiksberg Hospital, Center for Clinical Research and Prevention, Copenhagen, Denmark

DOP89: Final growth in paediatric Crohn's disease is impaired also in the era of biologics: a population-based analysis from the epiIIRN administrative cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Assa1, S. Cohen2, N. Asayag*3, N. Dan4, G. Focht4, O. Ledder4, N. Lederman5, E. Matz6, A. Cahan7, R. Balicer8, B. Feldman8, I. Brufman8, D. Turner4

1Schneider Children's Medical Center of Israel Hospital for Children, Petah Tikva, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, 4Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel, 5Meuhedet Health Services, Tel Aviv, Israel, Tel Aviv, Israel, 6Leumit Health Services, Tel Aviv, Israel, Tel Aviv, Israel, 7Maccabi Healthcare Services, Tel Aviv, Israel, Tel Aviv, Israel, 8Clalit Research Institute, Chief’s Office, Clalit Health Services, Tel Aviv, Israel, Tel Aviv, Israel

DOP90: The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD: results after 20 years of follow-up in the IBSEN study

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Ossum*1,2, Ø. Palm3, M. Cvancarova4, B. Moum1,2, M. L. Høivik1, The IBSEN study group1

1Oslo University Hospital, Ullevaal, Gastroenterology, Oslo, Norway, 2University of Oslo, Faculty of Medicine, Oslo, Norway, 3Oslo University Hospital, Rikshospitalet, Rheumatology, Oslo, Norway, 4OsloMet, Faculty of Public Health, Oslo, Norway